Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
…, GJ Fox, M Fréchet-Jachym, G Fregona, R Gayoso… - The Lancet, 2018 - thelancet.com
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs, …
to estimate the association of treatment success and death with the use of individual drugs, …
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
…, I Gaudiesiute, B Gavazova, R Gayoso… - European …, 2019 - Eur Respiratory Soc
The World Health Organization (WHO) recommends that countries implement pharmacovigilance
and collect information on active drug safety monitoring (aDSM) and management of …
and collect information on active drug safety monitoring (aDSM) and management of …
Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis
…, CL Daley, G Eather, R Gayoso… - European …, 2019 - Eur Respiratory Soc
Treatment of Mycobacterium abscessus pulmonary disease (MAB-PD), caused by M. abscessus
subsp. abscessus, M. abscessus subsp. massiliense or M. abscessus subsp. bolletii, is …
subsp. abscessus, M. abscessus subsp. massiliense or M. abscessus subsp. bolletii, is …
Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil
M Dalcolmo, R Gayoso, G Sotgiu… - European …, 2017 - Eur Respiratory Soc
Although clofazimine is used to treat multidrug-resistant tuberculosis (MDR-TB), there is
scant information on its effectiveness and safety. The aim of this retrospective, observational …
scant information on its effectiveness and safety. The aim of this retrospective, observational …
[HTML][HTML] Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort
…, A Garcia, I Gaudiesiute, B Gavazova, R Gayoso… - Pulmonology, 2021 - Elsevier
The World Health Organization (WHO) recommends countries introduce new anti-TB drugs
in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively …
in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively …
[HTML][HTML] Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
…, A Garcia, JM García-García, R Gayoso… - International journal of …, 2019 - Elsevier
The World Health Organization launched a global initiative, known as aDSM (active TB drug
safety monitoring and management) to better describe the safety profile of new treatment …
safety monitoring and management) to better describe the safety profile of new treatment …
[HTML][HTML] Predictors of mortality in multidrug-resistant tuberculosis patients from Brazilian reference centers, 2005 to 2012
R Gayoso, M Dalcolmo, JU Braga… - Brazilian Journal of …, 2018 - SciELO Brasil
Objectives To determine the main predictors of death in multidrug-resistant (MDRTB)
patients from Brazil. Design Retrospective cohort study, a survival analysis of patients treated …
patients from Brazil. Design Retrospective cohort study, a survival analysis of patients treated …
Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015
M Dalcolmo, R Gayoso, G Sotgiu… - European …, 2017 - Eur Respiratory Soc
The difficulties in managing multidrug-resistant tuberculosis (MDR-TB) and extensively drug-
resistant (XDR) TB are well known. The regimens are very expensive, often toxic, and …
resistant (XDR) TB are well known. The regimens are very expensive, often toxic, and …
Uptake of governmental social protection and financial hardship during drug-resistant tuberculosis treatment in Rio de Janeiro, Brazil
WE Rudgard, S Nancy, R Gayoso… - European …, 2018 - Eur Respiratory Soc
Despite most countries offering tuberculosis (TB) diagnosis and treatment free of charge, TB-related
costs remain an important barrier for accessing TB care [1]. TB-related costs include …
costs remain an important barrier for accessing TB care [1]. TB-related costs include …
[HTML][HTML] Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016
T Goldenberg, R Gayoso, R Mogami… - Jornal Brasileiro de …, 2020 - SciELO Brasil
Objetivo Avaliar características clínicas, tomográficas e microbiológicas dos pacientes com
doença pulmonar causada pela M. kansasii (DPMK) atendidos em unidade ambulatorial no …
doença pulmonar causada pela M. kansasii (DPMK) atendidos em unidade ambulatorial no …